Thoratec Corporation (THOR) – Financial and Strategic SWOT Analysis Review

Thoratec Corporation (THOR) – Financial and Strategic SWOT Analysis Review Cover

Single Licence: $125

Buy Now
customer(s) bought this report
BUY WITH CONFIDENCE

Shopping on CFDMaster.com is Safe and Secure. GUARANTEED!
All information is encrypted and handled by PayPal.com

Need Assistance?
Have you got questions about this report? Why not speak to one of our advisors. Email us at business@cfdmaster.com or call us at +61 (02) 8011 3208
# Pages
Market
Country
Single User
Site License
Enterprisewide
51
Medical Devices
United States

Thoratec Corporation (THOR) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

– Business description – A detailed description of the company’s operations and business divisions.
– Corporate strategy – Analyst’s summarization of the company’s business strategy.
– SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
– Company history – Progression of key events associated with the company.
– Major products and services – A list of major products, services and brands of the company.
– Key competitors – A list of key competitors to the company.
– Key employees – A list of the key executives of the company.
– Executive biographies – A brief summary of the executives’ employment history.
– Key operational heads – A list of personnel heading key departments/functions.
– Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
– Key manufacturing facilities – A list of key manufacturing facilities of the company.
– Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
– Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Thoratec Corporation (Thoratec) is a medical device company. It undertakes the research, development, manufacture and marketing of proprietary medical devices used for mechanical circulatory support for the treatment of heart failure (HF) patients. The major product of the company includes Thoratec Paracorporeal Ventricular Assist Device; Thoratec Implantable Ventricular Assist Device; HeartMate Left Ventricular Assist System; and HeartMate II Left Ventricular Assist System. The company also offers acute circulatory support products including CentriMag acute circulatory system and PediMag/PediVAS pediatric acute circulatory system. Thoratec’s products are marketed and sold in the US, Europe, Japan and other countries. The company markets its products to heart transplant hospitals and large cardiac surgery centers. Thoratec is headquartered in California, the US.

Thoratec Corporation Key Recent Developments

Feb 10, 2015: Thoratec Reports Fourth Quarter 2014 Results
Dec 19, 2013: Thoratec Presentation At J.P. Morgan Healthcare Conference To Be Webcast
Nov 27, 2013: Thoratec Announces Presentations At Investor Conferences For December 2013
Nov 05, 2013: Thoratec Announces Presentations At Investor Conferences For November 2013
Oct 30, 2013: Thoratec Reports Third Quarter 2013 Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
– The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
– The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
– Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
– Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
– Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Table of Contents

Section 1 – About the Company 6
Thoratec Corporation – Key Facts 6
Thoratec Corporation – Key Employees 7
Thoratec Corporation – Key Employee Biographies 8
Thoratec Corporation – Major Products and Services 9
Thoratec Corporation – Medical Equipment Pipeline Products Data 10
Thoratec Corporation Pipeline Products by Equipment Type 10
Thoratec Corporation Pipeline Products by Development Stage 12
Thoratec Corporation – History 14
Thoratec Corporation – Company Statement 17
Thoratec Corporation – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Section 2 – Company Analysis 19
Thoratec Corporation – Business Description 19
Thoratec Corporation – Corporate Strategy 20
Thoratec Corporation – SWOT Analysis 21
SWOT Analysis – Overview 21
Thoratec Corporation – Strengths 21
Strength – Focus on Innovation 21
Strength – Destination Therapy Approval: HeartMate II 21
Strength – Bridge-to-Transplantation Products 21
Thoratec Corporation – Weaknesses 22
Weakness – Product Safety Concerns 22
Weakness – Putative Class Action Suit 22
Thoratec Corporation – Opportunities 23
Opportunity – Clinical Trials 23
Opportunity – Increasing Incidence of Heart Failure 23
Opportunity – Inorganic Growth Strategies 23
Thoratec Corporation – Threats 24
Threat – Federal, State and International Laws and Regulations 24
Threat – Reliance of Specialized and Single Source Suppliers 24
Threat – Reimbursement Coverage from Government and Third Party Payers 24
Thoratec Corporation – Key Competitors 25
Section 3 – Company Financial Ratios 26
Financial Ratios – Capital Market Ratios 26
Financial Ratios – Annual Ratios 27
Performance Chart 28
Financial Performance 28
Financial Ratios – Interim Ratios 29
Financial Ratios – Ratio Charts 30
Section 4 – Company’s Lifesciences Financial Deals and Alliances 31
Thoratec Corporation, Medical Equipment, Deals By Year, 2009 to YTD 2015 31
Thoratec Corporation, Medical Equipment, Deals By Type, 2009 to YTD 2015 32
Thoratec Corporation, Recent Deals Summary 33
Section 5 – Company’s Recent Developments 34
Feb 10, 2015: Thoratec Reports Fourth Quarter 2014 Results 34
Dec 01, 2014: Thoratec Announces Completion Of Enrollment In The HeartMate III CE Mark Trial 36
Nov 05, 2014: Thoratec Reports Third Quarter 2014 Results 37
Oct 06, 2014: Thoratec Announces Additions To Senior Management Team 39
Sep 22, 2014: Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 40
Sep 09, 2014: Thoratec Announces Start Of Heartmate III U.S. Clinical Trial 41
Aug 06, 2014: Thoratec Reports Second Quarter 2014 Results 42
Jun 27, 2014: Thoratec Announces First HeartMate III Human Implant And Start Of CE Mark Trial 44
May 06, 2014: Thoratec Reports First Quarter 2014 Results 45
Mar 17, 2014: Thoratec Corporation Provides Additional Information Related to Worldwide Urgent Medical Device Correction Letter Regarding Use of the HeartMate II LVAS Pocket System Controller 46
Section 6 – Appendix 47
Methodology 47
Ratio Definitions 47
About GlobalData 51
Contact Us 51
Disclaimer 51



List of Tables
Thoratec Corporation, Key Facts 6
Thoratec Corporation, Key Employees 7
Thoratec Corporation, Key Employee Biographies 8
Thoratec Corporation, Major Products and Services 9
Thoratec Corporation Number of Pipeline Products by Equipment Type 10
Thoratec Corporation Pipeline Products by Equipment Type 11
Thoratec Corporation Number of Pipeline Products by Development Stage 12
Thoratec Corporation Pipeline Products by Development Stage 13
Thoratec Corporation, History 14
Thoratec Corporation, Subsidiaries 18
Thoratec Corporation, Key Competitors 25
Thoratec Corporation, Ratios based on current share price 26
Thoratec Corporation, Annual Ratios 27
Thoratec Corporation, Interim Ratios 29
Thoratec Corporation, Medical Equipment, Deals By Year, 2009 to YTD 2015 31
Thoratec Corporation, Medical Equipment, Deals By Type, 2009 to YTD 2015 32
Thoratec Corporation, Recent Deals Summary 33
Currency Codes 47
Capital Market Ratios 47
Equity Ratios 48
Profitability Ratios 48
Cost Ratios 49
Liquidity Ratios 49
Leverage Ratios 50
Efficiency Ratios 50



List of Figures
Thoratec Corporation Pipeline Products by Equipment Type 10
Thoratec Corporation Pipeline Products by Development Stage 12
Thoratec Corporation, Performance Chart (2010 – 2014) 28
Thoratec Corporation, Ratio Charts 30
Thoratec Corporation, Medical Equipment, Deals By Year, 2009 to YTD 2015 31
Thoratec Corporation, Medical Equipment, Deals by Type, 2009 to YTD 2015 32

Report Delivery

PDF SWOT Analysis Report An Electronic PDF copy of this Report will be sent to you via email.

Please allow up to 2 business days for the reports to arrive to your mailbox as some of our publishers prefer to send you the reports directly.

Purchase this Report today

Price: $125

Report Licences Explanation

* Single User: Electronic PDF copy delivered via email. Report can be used by individual purchaser only.

* Site License: Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.

* Enterprise Wide License: Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.

If you require a Site License or Enterprise Wide License please contact us to issue you an invoice.

Customers who Viewed this Report also Viewed

Risk warning: Your capital may be at risk. CFD trading is suitable for experienced traders and not beginners.